• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SC 13G/A 1 d294204dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 9)*

     

     

    Evogene Ltd.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    M4119S104

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. M4199S104

     

    1.    Names of Reporting Persons

     

    Macquarie Group Limited

    2.    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☒        (b)  ☐

    3.    SEC Use Only

     

    4.        Citizenship or Place of Organization

     

    Sydney, New South Wales Australia

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

       5.       

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    0

    9.        Aggregate Amount Beneficially Owned by Each Reporting Person

     

    183,210 deemed beneficially owned due to reporting person’s ownership of Macquarie Bank Limited whose individual holdings are shown on the following forms.

    10.    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.    Percent of Class Represented by Amount in Row (9)

     

    0.43%

    12.    Type of Reporting Person (See Instructions)

     

    HC

     

    Page 2 of 10


    CUSIP No. M4199S104

     

    1.    Names of Reporting Persons

     

    Macquarie Bank Limited

    2.    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☒        (b)  ☐

    3.    SEC Use Only

     

    4.        Citizenship or Place of Organization

     

    Sydney, New South Wales, Australia

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

       5.       

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    0

    9.        Aggregate Amount Beneficially Owned by Each Reporting Person

     

    183,210

    10.    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.    Percent of Class Represented by Amount in Row (9)

     

    0.43%

    12.    Type of Reporting Person (See Instructions)

     

    CO

     

    Page 3 of 10


    Item 1.

       (a)   

    Name of Issuer
    Evogene Ltd

       (b)   

    Address of Issuer’s Principal Executive Offices
    13 Gad Feinstein St., Park Rehovot, Rehovot, Israel

    Item 2.
       (a)   

    Name of Person Filing
    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Bank Limited

       (b)   

    Address of Principal Business Office or, if none, Residence
    The principal business address of Macquarie Group Limited Macquarie Bank Limited is 50 Martin Place Sydney, New South Wales, Australia.

       (c)   

    Citizenship
    Macquarie Group Limited, Macquarie Bank Limited - Sydney, New South Wales, Australia Corporation

       (d)   

    Title of Class of Securities
    Common Stock

       (e)   

    CUSIP Number
    M4199S104

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       (k)    ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                                                     

     

    Page 4 of 10


    Item 4.    Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

       (a)   

    Amount beneficially owned:

    See responses on the cover page hereto.

       (b)   

    Percent of class:

    See responses on the cover page hereto.

       (c)   

    Number of shares as to which the person has:

     

              (i)   

    Sole power to vote or to direct the vote

    See responses on the cover page hereto.

              (ii)   

    Shared power to vote or to direct the vote

    0

              (iii)   

    Sole power to dispose or to direct the disposition of

    See responses on the cover page hereto.

              (iv)   

    Shared power to dispose or to direct the disposition of

    0

     

    Item 5.    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following    ☒

     

    Item 6.    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A.

     

    Item 8.    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.    Notice of Dissolution of Group

    Not applicable.

     

    Page 5 of 10


    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited   

    February 11, 2022

       Date
    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
                            

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

    Macquarie Bank Limited   

    February 11, 2022

       Date
    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
                            

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Management Holdings, Inc.

      

    February 11, 2022

       Date

    /s/ Brian L. Murray

      
    Signature   

     

      

    Brian L. Murray

    Chief Compliance Officer

      
    Macquarie Investment Management Business Trust   

    February 11, 2022

       Date

    /s/ Brian L. Murray

      
    Signature   

     

      

    Brian L. Murray

    Chief Compliance Officer

      

     

    Page 6 of 10


    EXHIBIT A

    AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS

    AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”).

    WHEREAS, the parties hereto may be deemed to be the direct or indirect beneficial owners of the same equity securities for the purpose of the reporting requirements of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and

    WHEREAS, the regulations promulgated under Section 13(d) of the Exchange Act permit the joining of such beneficial owners in the filing of a single Joint Acquisition Statement reporting such ownership to the Securities and Exchange Commission.

    NOW, THEREFORE, in consideration of the mutual covenants herein contained, and each of the parties hereto intending to be legally bound, it is agreed as follows:

    1.    In the event that any two or more parties shall be deemed to be the direct or indirect beneficial owners of the same equity security required to be reported to the Securities and Exchange Commission such parties may join together in the filing of a Joint Acquisition Statement with respect to that security. Additional persons who may after the date hereof be deemed to be the direct or indirect beneficial owners of the same equity security as a party hereto and required to be reported to the Securities and Exchange Commission (a “New Party”) may be added as a party this agreement by signing a counterpart hereof. An amendment to this agreement is deemed effective upon the signature of such new party and the amendment of the applicable Annex which may be affixed to this agreement as amended. Each party hereto agrees that this agreement, as it may be amended from time to time as provided herein, is a valid and binding agreement of each such party.

    2.    With respect to each Joint Acquisition Statement in which a party joins, each party acknowledges that (a) it will be eligible under applicable regulations of the Securities and Exchange Commission to join in the filing and (b) it will be responsible for the timely filing of such statement and any amendments thereto and the completeness and accuracy of the information concerning such party; but each such party shall not be responsible for the completeness and accuracy of the information concerning the other parties making the filing, unless such party knows or has reason to believe that such information with respect to such other parties is inaccurate.

    3.    The parties consent to the inclusion of a copy of this agreement as an exhibit to any Joint Acquisition Statement filed on behalf of any of them.

     

    Page 7 of 10


    IN WITNESS WHEREOF, the parties hereto have executed this agreement by their duly authorized officers as of the date set forth above.

    DELAWARE FUNDS® BY MACQUARIE (listed on Annex A hereto)

    ATTEST BY:

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
                            

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
                            

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    MACQUARIE MANAGEMENT HOLDINGS, INC.

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
                            

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    THE MACQUARIE PARTIES (LISTED ON ANNEX B HERETO)

    ATTEST BY:

     

    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
                            

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

     

    Page 8 of 10


    Annex A— Delaware FundsSM by Macquarie

    DELAWARE GROUP EQUITY FUNDS I

    DELAWARE GROUP EQUITY FUNDS II

    DELAWARE GROUP EQUITY FUNDS IV

    DELAWARE GROUP EQUITY FUNDS V

    DELAWARE GROUP INCOME FUNDS

    DELAWARE GROUP LIMITED-TERM GOVERNMENT FUNDS

    DELAWARE GROUP CASH RESERVE

    DELAWARE GROUP GOVERNMENT FUND

    DELAWARE GROUP STATE TAX-FREE INCOME TRUST

    DELAWARE GROUP TAX-FREE FUND

    DELAWARE GROUP GLOBAL & INTERNATIONAL FUNDS

    DELAWARE GROUP ADVISER FUNDS

    DELAWARE VIP TRUST

    DELAWARE POOLED TRUST

    DELAWARE GROUP FOUNDATION FUNDS

    DELAWARE INVESTMENTS DIVIDEND AND INCOME FUND, INC.

    DELAWARE ENHANCED GLOBAL DIVIDEND AND INCOME FUND

    INVESTED PORTFOLIOS

    IVY HIGH INCOME OPPORTUNITIES FUND

    IVY FUNDS

    IVY VARIABLE INSURANCE PORTFOLIOSSM

    VOYAGEUR INSURED FUNDS

    VOYAGEUR INTERMEDIATE TAX FREE FUNDS

    VOYAGEUR MUTUAL FUNDS

    VOYAGEUR MUTUAL FUNDS II

    VOYAGEUR MUTUAL FUNDS III

    VOYAGEUR TAX FREE FUNDS

    DELAWARE INVESTMENTS COLORADO MUNICIPAL INCOME FUND, INC.

    DELAWARE INVESTMENTS NATIONAL MUNICIPAL INCOME FUND

    DELAWARE INVESTMENTS MINNESOTA MUNICIPAL INCOME FUND II, INC.

     

    Page 9 of 10


    Annex B — the Macquarie Parties

    Macquarie Group Limited

    Macquarie Bank Limited

    Macquarie Affiliated Managers (USA) Inc.

    Macquarie Affiliated Managers Holdings (USA) Inc.

    Macquarie Americas Holdings Pty Ltd.

    Macquarie B.H. Pty Limited

    Macquarie FG Holdings Inc.

    Macquarie Funding Holdings LLC

    Macquarie Investment Management Europe Limited

    EXHIBIT B

    Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021.

     

    Page 10 of 10

    Get the next $EVGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    SEC Filings

    View All

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    8/19/25 7:00:23 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    8/18/25 4:01:07 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    8/11/25 4:01:42 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene Reports Second Quarter 2025 Financial Results

    Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net". This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for Ag as of June 30, 2025.In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of

    8/19/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

    A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia and Gout. REHOVOT, Israel, Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the pioneering research group of Professor Ehud Gazit from Tel Aviv University, a world leader in the field of molecular self-assembly. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for a range of diseases

    8/12/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Second Quarter 2025 Financial Results Release

    Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel, July 29, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday, August 19, 2025.   Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be available online on the company's website a few day

    7/29/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

    RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

    11/24/21 7:31:39 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ROTH Capital initiated coverage on Evogene with a new price target

    ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

    10/8/21 8:30:09 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

    RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

    8/23/21 11:09:14 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

    A failure in metabolite breakdown leads to their ordered self-assembly into pathological aggregates, such as in Tyrosinemia and Gout. REHOVOT, Israel, Aug. 12, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the pioneering research group of Professor Ehud Gazit from Tel Aviv University, a world leader in the field of molecular self-assembly. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for a range of diseases

    8/12/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

    Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make

    3/6/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

    Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its l

    12/19/23 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Evogene Ltd

    SC 13G - Evogene Ltd. (0001574565) (Subject)

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Financials

    Live finance-specific insights

    View All

    Evogene Reports Second Quarter 2025 Financial Results

    Conference call and webcast: today, August 19, 2025, 9:00 am ET Financial Highlights: The financial results for the first half of 2025 of Lavie Bio, a subsidiary of Evogene and the MicroBoost AI for Ag operations, are presented as a single-line item in Evogene's consolidated statements of profit and loss for the first half of 2025. Their results are included under the line titled - "Loss from operations held for sale, net". This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for Ag as of June 30, 2025.In the first half of 2025, total revenues amounted to approximately $3.2 million, compared to $2.3 million in the first half of

    8/19/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Second Quarter 2025 Financial Results Release

    Zoom conference call scheduled for August 19, 2025, 9:00 AM ET REHOVOT, Israel, July 29, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Tuesday, August 19, 2025.   Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be available online on the company's website a few day

    7/29/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports First Quarter 2025 Financial Results

    Conference call and webcast: today, May 21, 2025, 9:00 am ET Financial Highlights: In the first quarter of 2025, total revenues were approximately $2.4 million, compared to approximately $4.2 million in the first quarter of 2024. The first quarter of 2024 revenues included license fee payments totaling $3.5 million - $2.5 million from Lavie Bio's license fee under its collaboration with Corteva, and $1.0 million from AgPlenus' license fee under its collaboration with Bayer. The primary driver of revenue in the first quarter of 2025 was an increase in seed sales by Casterra.During the fourth quarter of 2024 and the beginning of 2025, Evogene established an expense reduction plan which is expe

    5/21/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials